The FDA has received 11,925 adverse event reports for dogs that name Trilostane.
- 11,925 reports name Trilostane in dogs, which is 1.2% of all 1,001,380 dog reports. A report counts under every active ingredient it names.
- 46% are marked serious and 11% record a death or euthanasia; across all dog reports those figures are 29% and 5.4%.
- 15% are complaints that the product did not work (38% across all dog reports).
- The clinical signs reported most are vomiting, lethargy and hyperkalaemia.
- The FDA lists 1 approved animal drug application containing Trilostane for dogs, the earliest approved in 2008.
- None of this is a rate. The FDA data does not record how many dogs were given Trilostane, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All dog reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 5,479 | 46% | 29% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 1,346 | 11% | 5.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 1,765 | 15% | 38% |
| Seizurea seizure or convulsion is among the clinical signs | 367 | 3.1% | 4.4% |
| Not used per labelthe report says the product was not used the way its label directs | 6,668 | 56% | 21% |
Where on the body do the reported signs sit?
Not on the body: Whole body 11% Did not work 6.4% How it was given 5.3%
- Blood and organ tests41%hyperkalaemia, elevated serum alkaline phosphatase (sap), elevated alanine aminotransferase (alt), elevated blood urea nitrogen (bun) and 7 more
- Stomach and gut27%vomiting, weight loss, diarrhoea, decreased appetite and 1 more
- Whole body11%lethargy, death by euthanasia
- Thirst and urination8.3%polydipsia, polyuria, urinary tract infection
- Did not work6.4%ineffective, cushings, lack of efficacy
- How it was given5.3%underdose
- Heart and breathing2.1%panting
Each figure is a share of sign mentions among the 25 signs reported most for Trilostane in dogs. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- Vomiting2,021 17%
- Lethargy1,973 17%
- Hyperkalaemia1,751 15%
- Elevated serum alkaline phosphatase (SAP)1,689 14%
- Weight loss1,496 13%
- Diarrhoea1,455 12%
- Underdose1,431 12%
- Elevated alanine aminotransferase (ALT)1,399 12%
Reports received per year
Is it approved for dogs?
The FDA lists 1 approved animal drug application containing Trilostane for dogs, the earliest approved in 2008.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| Vetoryl CapsulesDechra Veterinary Products LLC | Capsule RX | Dog | 2008 | 141-291 |
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Maropitant in dogs11,886
- Lotilaner in dogs12,797
- Deracoxib in dogs11,012
- Nitenpyram in dogs10,786
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.